

## **Determinants of human papillomavirus coinfections among Montreal university students: the influence of behavioural and biological factors**

Michaela A. Smith<sup>1</sup>, Pierre-Paul Tellier<sup>2</sup>, Michel Roger<sup>3</sup>, Francois Coutlée<sup>3,4</sup>, Eduardo L. Franco<sup>4,5</sup>, Harriet Richardson<sup>1</sup>

### **Affiliations:**

<sup>1</sup> Department of Public Health Sciences, Queen's University, Kingston, Canada

<sup>2</sup> Department of Family Medicine, McGill University, Montreal, Quebec, Canada

<sup>3</sup> Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal and Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada

<sup>4</sup> Department of Oncology, McGill University, Montreal, Quebec, Canada

<sup>5</sup> Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada

**Running title:** Behavioural and biological determinants of HPV coinfections

**Key words:** human papillomavirus, coinfections, HLA, determinants, repeated measures

**Financial support:** MAS was supported by an Ontario Graduate Scholarship from the Government of Ontario, Canada. This work was also supported by grants CNR-83320 and MOP-5311 from the Canadian Institutes of Health Research to ELF.

### **Correspondence:**

Dr. Harriet Richardson  
Queen's University, Department of Public Health Sciences,  
Divisions of NCIC Clinical Trials Group & Cancer Care and Epidemiology  
10 Stuart Street, Kingston, Ontario, Canada K7L 3N6  
Phone: 613-533-6430  
Email: [hrichardson@ctg.queensu.ca](mailto:hrichardson@ctg.queensu.ca)

**Conflict of Interest Statement:** The authors do not declare any conflict of interest related to the topic of this article. ELF has served as an occasional advisory board member or consultant to companies involved with HPV vaccines (GlaxoSmithKline and Merck), HPV diagnostics (Gen-Probe, Roche, Qiagen), and cervical cancer cytology screening (Cytoc, Ikonisys). FC has received grants through his institution from Merck and Roche, as well as honoraria from Merck and Roche for lectures.

**Word Count:** 3,965

**Number of Tables and Figures:** 4

## ABSTRACT

**Background:** HPV coinfections are common among HPV-infected individuals, but the significance and etiology of these infections remain unclear. Though current evidence suggests that women with coinfections have increased HPV exposure (i.e. more sexual partners), it is also hypothesized that these women may represent a subgroup with increased biological susceptibility. This study sought to examine determinants of coinfections in a cohort of young women, examining both behavioural and biological factors related to HPV acquisition over time.

**Methods:** Female university students (n=537) in Montreal, Canada were followed for 2 years at 6-month intervals. At each visit, cervical specimens were collected for cytology and HPV testing, and women completed a questionnaire about lifestyle and behaviour. HLA alleles were typed from purified DNA collected from cervical specimens. Two definitions of coinfections were used: cumulative coinfection over follow-up and concurrent coinfection at each visit. Multiple logistic regression was used to determine predictors of both cumulative and concurrent coinfections using baseline and time-dependent covariates.

**Results:** The most consistent determinant of coinfection occurrence was number of sexual partners, though several genes of the immune response (HLA-DQB1\*06:02, HLA-G\*01:01:03, HLA-G\*01:01:05) were also identified as significant predictors of cumulative coinfections.

**Conclusions:** HPV coinfections mainly occur due to increased sexual activity, but biological susceptibility may also be involved in a subset of women. Immunological factors may put women at greater risk of coinfections over the long-term, but short-term risk is almost exclusively driven by modifiable sexual behaviours.

**Impact:** Additional research should continue to further identify immunological biomarkers of HPV susceptibility.

## INTRODUCTION

Coinfections with multiple types of human papillomavirus (HPV) are a common occurrence, particularly among young, sexually active women (1-5). Although the significance of these coinfections in the etiology of cervical cancer has been the subject of debate (6-8), there is evidence to suggest that coinfections may be associated with an increased risk of precancerous cervical lesions when compared to infections with only one type of HPV (also referred to as mono-infections) (9-13).

To date, most studies that have examined determinants of HPV coinfections have largely focused on behavioural factors such as sexual activity, with little attention given to biological predictors, such as the genetic make-up or immune response of the host (14-19). As such, the role played by biological susceptibility in the development of coinfections remains somewhat unclear, although indirect evidence supporting this relationship can be seen in the high rates of HPV coinfections observed among HIV-infected individuals (20-22), and among younger women, in which natural immunity to HPV has not yet developed (9, 14, 16, 18, 19). Indeed, despite the definitive role played by sexual activity in determining a woman's exposure to HPV, it has been suggested that the occurrence of HPV coinfections cannot be explained by sexual behaviours alone (8, 14, 23).

The human immune response is affected by a complex interplay of factors, some of which are directly modifiable (e.g. smoking status, nutrient consumption) and some of which are less so (e.g. age, genetic make-up). Of the genetic factors that may be potentially involved in cervical cancer risk, some of the strongest evidence has been found for genes in the human leukocyte antigen (HLA) system, as these play a crucial role in immune function and in determining an individual's resistance to infections (24, 25).

The HLA system comprises a cluster of highly polymorphic genes that encode for various cell-surface molecules, which are divided into diverse classes (Class Ia, Class Ib and Class II) (24, 26). Through their role in antigen presentation, HLA molecules are thought to be critically involved in cell-mediated immune recognition and viral clearance (25, 26), and as such, there is strong biological

plausibility for the HLA system to be involved in the acquisition of HPV coinfections. Indeed, although HLA alleles have been implicated in HPV acquisition (27-29), persistence (28, 30), and carcinogenic progression (24, 26, 31, 32), no studies to date have looked at the impact of specific HLA alleles on the risk of developing HPV coinfections.

At the same time, however, modifiable factors such as smoking status, vegetable consumption and condom use have also been associated with the occurrence of HPV more generally (33, 34), though studies of these factors in relation to coinfections have been mixed (8, 14-16, 18). As such, the aim of this study was to investigate the influence of both biological and behavioural predictors on the acquisition of HPV coinfections, with a particular focus on HLA alleles as candidate immune factors. Importantly, because modifiable risk factors may operate at different time-scales than factors which are non-modifiable, we have chosen to examine potential determinants over both short-term and long-term intervals, using multiple definitions of HPV coinfection occurrence.

## **MATERIALS AND METHODS**

### **Study Population and Procedures**

The McGill-Concordia Cohort, a prospective study of the natural history of HPV infection and cervical neoplasia among female university students, has been described in detail elsewhere (35). Recruitment of the cohort took place between November 1996 and January 1999 among female students attending either the McGill or Concordia University health clinics in Montreal, Quebec. Participants were eligible for the study if they planned to remain in Montreal for 2 years and had not been treated for cervical abnormalities in the past year. Eligible participants were required to make 5 clinic visits in total, returning every 6 months over a 2-year period.

At each visit, samples of endocervical and ectocervical cells were collected using two Accelon cervical biosamplers (Medscand Inc, Hollywood FL). A Pap smear was prepared with the first sampler, and the cervical cells collected with the second sampler were used for HPV DNA testing. At enrollment, a

self-administered questionnaire was used to collect information on socio-demographics, diet, smoking, alcohol use, reproductive history, medical history and sexual practices. At each subsequent visit, updated information on all exposures except diet and socio-demographics was collected.

### **HPV DNA Detection**

HPV DNA was purified from the cervical samples using QIAamp columns (Qiagen) and amplification of  $\beta$ -globin DNA with PC04 and GH20 primers was used to verify the integrity of processed DNA. Specimens that were  $\beta$ -globin positive were further tested for the presence of HPV DNA using a polymerase chain reaction (PCR) protocol with the L1 consensus primers MY09/MY11 and HMB01. HPV typing of the amplified products was done using a line blot assay (Roche Molecular Systems) for the detection of 27 HPV types (35).

### **HLA genotyping**

For the sake of analytical efficiency we restricted HLA genotyping to women who met one of two conditions: (a) women who participated in the study for at least 3 visits, or (b) women who had a persistent infection with the same HPV type for 2 consecutive visits (27). HLA alleles were typed from purified DNA obtained from cervical specimens collected at enrollment, using PCR amplification of sequence-specific primers for HLA-B\*07, DQB1\*03, DQB1\*06:02, DRB1\*13, DRB1\*15:01, and direct DNA sequence analysis for E\*01:01, E\*01:03, G\*01:01:01, G\*01:01:02, G\*01:01:03, G\*01:01:05, G\*01:01:07, G\*01:01:08, G\*01:03, G\*01:04:01, G\*01:04:03, G\*01:05N, the details of which can be found elsewhere (27, 28). These HLA types were chosen a priori based on consistent published evidence to support their role in susceptibility to both HPV infection (27-30) and cervical cancer (24, 26, 31, 32).

### **Statistical Analysis**

Two definitions of HPV coinfections were used in order to examine potential predictors at different time points. A *cumulative* coinfection was defined as 2+ types of HPV detected at any point over the study period, i.e. during a single visit or over the course of multiple visits. By contrast, a *concurrent*

coinfection was limited to the detection of 2+ types of HPV during a single clinic visit, i.e. at the same point in time. As such, we did not distinguish between women who acquired one new HPV infection in addition to a previous infection and women who acquired 2 new HPV infections concomitantly at a given visit. Coinfection outcomes were not mutually exclusive: a woman with a concurrent coinfection at one visit was also counted as having a cumulative coinfection overall, and would thus contribute to the analyses for each outcome.

Unconditional multivariate logistic regression was used to estimate associations between exposure variables and each coinfection outcome. Separate models were used to contrast women with coinfections to women with monoinfections, and also to women who remained HPV-negative. The reasoning behind this choice was our hypothesis that each comparison might yield different aspects of coinfection etiology. In particular, we hypothesized that the coinfection v. HPV-negative model would be where sexual activity exerted the greatest influence on coinfection occurrence, as these groups of women would likely have the most divergent risk profiles. By contrast, we hypothesized that sexual activity would be less important in the coinfection v. monoinfection (all HPV+) model and that this might be where more subtle determinants of risk (e.g. biological factors) would emerge.

The choice of which exposures to investigate as potential determinants was made on the basis of the published literature and on the data that was available in our cohort. With the exception of the HLA alleles, all exposure data was obtained from the baseline and follow-up questionnaires described previously. For the HLA alleles, a 'dominant' allele approach was used, such that women who were homozygous or heterozygous for a given allele were compared to women in whom the allele was absent.

Potential determinants of *cumulative* coinfections were examined using exposures assessed at baseline only, to best represent the effects of non-modifiable risk factors that do not vary over time. Potential determinants of *concurrent* coinfections were examined using repeated measures models with both baseline and time-dependent exposures as candidate predictors. The purpose of the repeated measures analysis was to explain the presence of a coinfection at a particular visit using data from the

time interval just prior to that visit (~6 months). This approach also allowed us to make full use of the cohort data since each woman could contribute multiple visits to the analysis.

For the model involving repeated measures, the generalized estimating equations (GEE) extension of logistic regression was used to adjust the ORs and standard errors for the within-subject correlation between multiple visits by the same individual (36). As it was assumed that observations from visits closer together in time would be more correlated, a first-order auto-regressive working correlation matrix was used. Prevalent coinfections detected at enrollment were excluded from this analysis as we felt these infections could be the result of exposures that were not necessarily recent, and which were already captured in the cumulative model. As such, the repeated measures analysis only examined determinants of concurrent coinfections that were newly detected over follow-up.

In the cumulative analysis, we constructed bivariate logistic regression models for baseline exposures and cumulative HPV outcomes. Variables that were significant at  $p < 0.25$  were then considered as candidates for inclusion in the multivariate models. Selection of independent variables into the final models was based on backward elimination using a significance level of  $p < 0.1$ .

After the construction of the cumulative outcome models, significant baseline variables from this analysis were used as a starting point for the GEE models. In addition to the baseline exposures, all variables for which there was time-dependent data were also considered as candidate predictors in this analysis. For a coinfection at visit  $v$ , a time-dependent variable referred to an exposure that occurred in the interval between visit  $v-1$  and visit  $v$ . Final multivariate GEE models were again selected using backward elimination at a significance level of  $p < 0.1$ . All statistical analyses were conducted using SAS Version 9.2 (Cary, NC).

## RESULTS

Baseline demographic and sexual behaviour variables for this cohort have been reported in detail previously (27, 35). The mean age of the cohort was 23 years at enrollment and the vast majority (>80%)

of women described themselves as white. HPV infection status did not differ with respect to age, ethnicity or socioeconomic status, though women who became HPV-positive tended to have been younger at first intercourse, and to have had more lifetime sex partners. At enrollment, nearly half of the women (45%) had had 5 or more lifetime sex partners, a proportion that increased to 60% by the end of the study.

After exclusions for missing data on HLA alleles and other covariates of interest, there were 537 women and 2499 individual visits with complete data for analysis. 65 additional visits were excluded from the concurrent analysis because they contained prevalent coinfections at enrollment (Figure 1).

### **Cumulative coinfection status: bivariate results**

Table 1 shows the bivariate associations between baseline exposures (significant at  $p < 0.25$ ) and cumulative HPV infection status. Of the 537 women, there were 115 (21.4%) with a monoinfection and 192 (35.8%) with a coinfection detected cumulatively over the study. 230 women (42.8%) remained HPV-negative throughout follow-up.

Several strong associations were observed in the coinfection v. HPV-negative model (Table 1). In particular, variables that were significantly associated with occurrence of coinfections included: age at first intercourse, number of sex partners (both lifetime and new), history of anal sex, history of yeast infections, history of STIs (particularly *Chlamydia*), alcohol consumption and cigarette smoking. Though no associations were found for Black/Hispanic participants, women of Asian descent appeared to be significantly protected compared to white women. In the second bivariate model comparing coinfections to monoinfections, there were far fewer significant associations: only number of new sex partners, frequency of sex per week (inconsistently) and the HLA-G\*01:01:01 allele were associated with cumulative coinfection occurrence.

### **Cumulative coinfection status: multivariate results**

Table 2 shows the multivariate associations for all variables retained in the final cumulative models, mutually adjusted for one another. In the first model, compared to women who remained HPV-negative, significant baseline predictors of developing a cumulative coinfection included having  $\geq 2$



lifetime sex partners, having  $\geq 2$  new sex partners in the year prior to enrollment (OR=3.87; 95% CI: 2.16-6.93), having a previous history of STIs (OR=2.96; 95% CI: 1.31-6.69) and having the HLA-DQB1\*06:02 allele (OR=1.83; 95% CI: 1.08-3.09). Being age 27 or older at enrollment was also significantly protective (OR=0.34; 95% CI: 0.17-0.67). In the second model, in which all women were HPV-positive, significant predictors of cumulative coinfections included having  $\geq 2$  new sex partners in the last year (OR=2.74; 95% CI: 1.48-5.08) as well as possessing the HLA-G\*01:01:05 (OR=6.44; 95% CI: 1.66-24.95) allele. In contrast, possessing the HLA-G\*01:01:03 allele was significantly protective (OR=0.34; 95% CI: 0.14-0.81). Though a very strong association was found for the former allele in particular, it should be noted that this result was based on relatively few women (n=15), due to the rarity of this allele in the cohort (Table 1). In addition, the DQB1\*06:02 allele was also associated with increased odds of coinfection in this comparison, though it did not reach statistical significance (OR=1.62; 95% CI: 0.90-2.93).

#### **Concurrent coinfection status: multivariate results**

In the repeated measures models, the 537 subjects from the cumulative analysis generated 2434 visits where incident coinfection status could be assessed. Of these, there were 746 HPV-positive visits (30.6%) and 266 visits (10.9%) with concurrent coinfections detected. Table 3 presents the results of the multivariate repeated measures models for predictors of concurrent coinfections at individual visits. These results differed slightly from the cumulative models, though age and number of sex partners were still the most important determinants of coinfection, particularly when visits with coinfections were contrasted with HPV-negative visits.

In terms of the time-dependent exposures, aspects of sexual behaviour appeared to be the most important factors associated with concurrent coinfections in both models. In particular, number of new sex partners, irregular use of oral contraceptives (OCs) and never using condoms were all significantly associated with coinfection occurrence in at least one of the models. Number of new sex partners was the only significant predictor found in both models, where an effect was seen for having any new sex partner

in the last 12 months. Women who reported never using condoms since their previous visit were also more likely to have coinfections detected in both comparisons, although the associations were only borderline significant. Notably, irregular use of OCs was also positively associated with coinfection occurrence (OR=1.88; 95% CI: 1.08-3.26) but only in comparison to women with monoinfections. Though age at first intercourse and frequency of sex per week were both significant at  $p < 0.1$ , none of the confidence intervals were significantly different from unity and no clear trend seemed to be evident for these variables.

## DISCUSSION

In this study we investigated both behavioural and biological predictors of HPV coinfection occurrence in a longitudinal cohort of young women. In order to gain the greatest amount of information from this analysis, we used two different comparison groups and two definitions of coinfections, and examined both baseline and time-varying risk factors. In the models that included HPV-negative women, we expected the most important predictors of coinfections to be predominantly related to sexual activity, and so these models served as a good comparison to the exclusively HPV-positive models, in which we hypothesized that sexual factors might be less important. Though some studies have reported increased sexual activity to be the main explanation for coinfection occurrence (15, 37), there has been little research into biological factors that may also be involved in modulating individual susceptibilities. By including several exposures purported to affect the immune response (i.e. HLA alleles, smoking status, vegetable consumption), we hoped to tease out some of these more subtle predictors of coinfection occurrence.

As expected, in the final multivariate models examining predictors of cumulative coinfections, we found several differences in the two comparison models, each revealing slightly different aspects of coinfection etiology. As hypothesized, the coinfection v. HPV-negative model mainly reflected traditional risk factors for HPV infection (e.g. age) as well as markers of increased sexual activity (e.g. more lifetime sex partners, history of STIs). Number of new sex partners was the only significant predictor of

coinfections that appeared in both models, likely because it is a proxy for exposure to new types of HPV. Notably, three HLA alleles were retained as significant predictors in the final cumulative models, and seemed to be particularly associated with coinfections among HPV-positive women. In an effort to investigate whether there might be greater frailty among women who acquired higher numbers of coinfections over follow-up, we re-ran our coinfection v. monoinfection model post-analysis comparing women who acquired 2-3 types (n=131) and 4+ types (n=61) to those who only acquired only 1 type over follow-up (n=115). While most of the variables did not change markedly, we did observe a striking effect for HLA-G\*01:01:05 among women who acquired 4+ types, as the strength of the association increased considerably: OR=11.01; 95% CI: 1.63-74.34 (data not shown). Though this effect was only based on 6 women due to the rarity of this allele in the cohort, this finding bolsters the notion that certain HLA alleles could mediate susceptibility to coinfections with many HPV types. Future studies with larger sample sizes should attempt to investigate this relationship further.

In the repeated measures models, the results were generally similar to the cumulative models, though we had the added benefit of assessing predictors that could vary over time. As such, we identified several time-dependent predictors of concurrent coinfections, namely, new sex partners, condom use and OC use. Women who reported ‘never’ using condoms since their previous visit had significantly increased odds of concurrent coinfection in both of the repeated measures models, whereas irregular (i.e. ‘sometimes’) use of OCs since the previous visit was a significant predictor of concurrent coinfection among HPV-positive women only. Though we restricted this analysis to coinfections that were newly *detected*, an important caveat of these models is that we were not able to distinguish between newly *acquired* HPV infections and reactivation of latent infections that women may have had previously. Although there is undoubtedly some reactivation taking place in our cohort, the strong relationship we found for new sex partners in particular suggests that the occurrence of coinfections is being largely driven by new HPV acquisition.

In terms of biological factors, we found 3 HLA alleles to be significantly associated with coinfections in the models based on cumulative HPV status. As we had hypothesized, the effect was strongest in the all HPV+ model (where HPV infection status was effectively ‘controlled for’), and only after adjustment for number of new sexual partners. As the HLA system is critical to the host immune response (25), it is conceivable that these alleles may play an important role in both immune recognition and clearance of the virus. Indeed, because coinfections themselves are a product of both HPV acquisition and persistence (i.e. the longer an infection persists, the greater the chance it will be detected and overlap with a new infection), it is possible that these HLA alleles may be operating at several critical points in the course of infection. Indeed, HLA-G acts as negative regulator of the immune response by preventing antigen recognition and T-cell migration, as well as through suppression of T and NK cells’ cytotoxic effects. Thus, the immunosuppressive properties of HLA-G may contribute to both the susceptibility and persistence of HPV infections (38).

As this is the first study to explicitly explore the role of HLA alleles in the development of HPV coinfections, it is somewhat difficult to contextualize these results with other studies in the literature. Nevertheless, the HLA-DQB1\*06:02 allele has been linked to both cervical cancer and malignant precursor lesions in several studies (24, 26, 39), and in a previous study in this cohort, the allele was associated with both high-risk HPV and HPV16 positivity, though the associations did not reach statistical significance (27). Another previous study in this cohort also found the HLA-G\*01:01:02 allele to be associated with both increased cumulative risk and persistence of HPV16 (28), and this allele was also recently linked to invasive cervical cancer (32).

Both the HLA-G\*01:01:03 and HLA-G\*01:01:05 alleles associated with coinfections here were also previously found to be associated with increased odds of certain low-risk HPV infections in this cohort, but not among women purported to be highly exposed to HPV (28). The DNA sequences of the HLA-G\*01:01:03 and HLA-G\*01:01:05 alleles are almost identical except for the presence of a synonymous mutation (proline) at codon 57 in the HLA-G\*01:01:03 allele. Because the polymorphism in

codon 57 does not change the HLA-G amino acid composition and presumably its function, it is difficult to deduce the mechanism by which a silent mutation could have a direct influence on susceptibility to coinfections at this time. However, this mutation is in the vicinity of Glu-63, which interacts with the P2 position of loaded peptide (40). Therefore, it is possible that this mutation could affect the loading of viral peptides and consequently influence cell-mediated immune responses.

The results of our repeated measures analysis are also noteworthy because conflicting results have been found for condom use and OC use in other studies of coinfections. For instance, though none of the longitudinal studies of coinfections have identified condom use as a significant predictor, it was associated with decreased occurrence of coinfections in two cross-sectional studies (18, 41). Although condom use has not been found to have the consistent protective effect with HPV that it has with other STIs (42, 43), it is likely that when used properly, condoms convey at least some degree of protection, either by acting as a protective barrier against skin-to-skin transmission or by decreasing HPV viral load (34). OC use has also been found to have an equivocal effect on coinfection risk (15, 16); however, it is also strongly associated with sexual activity, and residual confounding may exist even after adjusting for number of sexual partners (44, 45). Similarly, it is worth noting that sexual factors such as condom use and OC use may also play a role in HPV susceptibility, through modifications to the cervical immune environment. In particular, recent research has shown that rapid changes in female sex hormones as well as exposure to seminal fluid (through non-condom use) can have profound effects on the cervical microenvironment and immune response (46).

### **Strengths and Conclusions**

The main strengths of this study were its longitudinal, repeated measures design and the availability of high quality biological and behavioural data on much of our cohort. This allowed us to examine a wide range of potential determinants of HPV coinfections and to assess their relative effect(s) by controlling for other relevant exposures. The repeated measures design also allowed for the assessment of determinants that vary over time, which may better represent temporal etiologic associations. We were

limited, however, by the rarity of certain HLA alleles, which resulted in some findings being based on relatively small numbers. Nevertheless, this research adds to the current understanding of HPV coinfection occurrence, and provides some of the first evidence of the role played by biological susceptibility in an otherwise healthy cohort of young women.

In conclusion, in this study assessing predictors of HPV coinfections in a population of female university students, we have confirmed that coinfections are caused by a complex interplay of factors affecting both exposure and susceptibility to HPV. In particular, we identified multiple markers of increased sexual activity and poor contraceptive practices as modifiable risk factors for coinfection occurrence, and we found several HLA alleles to be significant predictors of coinfections, even after controlling for more traditional risk factors such as age and sexual activity. Additional research is needed to further identify and pinpoint immunological biomarkers of HPV susceptibility, particularly among women who acquire many types of HPV over short periods of time, as these women may represent an important risk subgroup for further cervical disease.

## **ACKNOWLEDGMENTS**

We thank Gail Kelsall for managing subjects and Annie Jeanneau, Marie-Claude Faucher, and Helene Voyer for HLA and HPV testing. We thank Roche Molecular Systems for providing reagents for the performance of the Line blot assay.

## REFERENCES

1. Vaccarella S, Franceschi S, Snijders PJ, Herrero R, Meijer CJ, Plummer M. Concurrent infection with multiple human papillomavirus types: pooled analysis of the IARC HPV Prevalence Surveys. *Cancer Epidemiology Biomarkers & Prevention*. 2010;19:503-10.
2. Thomas KK, Hughes JP, Kuypers JM, Kiviat NB, Lee S-K, Adam DE, et al. Concurrent and sequential acquisition of different genital human papillomavirus types. *Journal of Infectious Diseases*. 2000;182:1097-102.
3. Méndez F, Muñoz N, Posso H, Molano M, Moreno V, van den Brule AJ, et al. Cervical coinfection with human papillomavirus (HPV) types and possible implications for the prevention of cervical cancer by HPV vaccines. *Journal of Infectious Diseases*. 2005;192:1158-65.
4. Chaturvedi AK, Myers L, Hammons AF, Clark RA, Dunlap K, Kissinger PJ, et al. Prevalence and clustering patterns of human papillomavirus genotypes in multiple infections. *Cancer Epidemiology Biomarkers & Prevention*. 2005;14:2439-45.
5. Liaw K-L, Hildesheim A, Burk RD, Gravitt P, Wacholder S, Manos MM, et al. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. *Journal of Infectious Diseases*. 2001;183:8-15.
6. Plummer M, Schiffman M, Castle PE, Maucourt-Boulch D, Wheeler CM. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. *Journal of Infectious Diseases*. 2007;195:1582-9.
7. Plummer M, Vaccarella S, Franceschi S. Multiple human papillomavirus infections: the exception or the rule? *Journal of Infectious Diseases*. 2011;203:891-3.
8. Chaturvedi AK, Katki HA, Hildesheim A, Rodríguez AC, Quint W, Schiffman M, et al. Human papillomavirus infection with multiple types: pattern of coinfection and risk of cervical disease. *Journal of Infectious Diseases*. 2011;203:910-20.
9. Rousseau M-C, Villa LL, Costa MC, Abrahamowicz M, Rohan TE, Franco E. Occurrence of cervical infection with multiple human papillomavirus types is associated with age and cytologic abnormalities. *Sexually Transmitted Diseases*. 2003;30:581-7.
10. Fife KH, Cramer HM, Schroeder JM, Brown DR. Detection of multiple human papillomavirus types in the lower genital tract correlates with cervical dysplasia. *Journal of Medical Virology*. 2001;64:550-9.
11. Trottier H, Mahmud S, Costa MC, Sobrinho JP, Duarte-Franco E, Rohan TE, et al. Human papillomavirus infections with multiple types and risk of cervical neoplasia. *Cancer Epidemiology Biomarkers & Prevention*. 2006;15:1274-80.
12. Trottier H, Mahmud S, Prado JCM, Sobrinho JS, Costa MC, Rohan TE, et al. Type-specific duration of human papillomavirus infection: implications for human papillomavirus screening and vaccination. *Journal of Infectious Diseases*. 2008;197:1436-47.

13. van der Graaf Y, Molijn A, Doornewaard H, Quint W, van Doorn L-J, van den Tweel J. Human papillomavirus and the long-term risk of cervical neoplasia. *American Journal of Epidemiology*. 2002;156:158-64.
14. Moscicki A-B, Ma Y, Jonte J, Miller-Benningfield S, Hanson E, Jay J, et al. The role of sexual behavior and human papillomavirus persistence in predicting repeated infections with new human papillomavirus types. *Cancer Epidemiology Biomarkers & Prevention*. 2010;19:2055-65.
15. Ho GY, Studentsov Y, Hall CB, Bierman R, Beardsley L, Lempa M, et al. Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles. *Journal of Infectious Diseases*. 2002;186:737-42.
16. Nielsen A, Kjaer SK, Munk C, Iftner T. Type-specific HPV infection and multiple HPV types: prevalence and risk factor profile in nearly 12,000 younger and older Danish women. *Sexually Transmitted Diseases*. 2008;35:276-82.
17. Rousseau M-C, Abrahamowicz M, Villa LL, Costa MC, Rohan TE, Franco EL. Predictors of cervical coinfection with multiple human papillomavirus types. *Cancer Epidemiology Biomarkers & Prevention*. 2003;12:1029-37.
18. Molano M, Posso H, Weiderpass E, Van den Brule A, Ronderos M, Franceschi S, et al. Prevalence and determinants of HPV infection among Colombian women with normal cytology. *British Journal of Cancer*. 2002;87:324-33.
19. Lazcano-Ponce E, Herrero R, Muñoz N, Cruz A, Shah KV, Alonso P, et al. Epidemiology of HPV infection among Mexican women with normal cervical cytology. *International Journal of Cancer*. 2001;91:412-20.
20. Levi JE, Fernandes S, Tateno AF, Motta E, Lima LP, Eluf-Neto J, et al. Presence of multiple human papillomavirus types in cervical samples from HIV-infected women. *Gynecologic Oncology*. 2004;92:225-31.
21. Levi JE, Kleter B, Quint WG, Fink MC, Canto CL, Matsubara R, et al. High prevalence of human papillomavirus (HPV) infections and high frequency of multiple HPV genotypes in human immunodeficiency virus-infected women in Brazil. *Journal of Clinical Microbiology*. 2002;40:3341-5.
22. Clifford GM, Goncalves MAG, Franceschi S. Human papillomavirus types among women infected with HIV: a meta-analysis. *AIDS*. 2006;20:2337-44.
23. Cervantes JL. Multiple human papillomavirus infection: Don't forget the genetic background. *Journal of Infectious Diseases*. 2011;204:1816-.
24. de Araujo Souza PS, Sichero L, Maciag PC. HPV variants and HLA polymorphisms: the role of variability on the risk of cervical cancer. *Future Oncology*. 2009;5:359-70.
25. Delves PJ, Roitt I. The immune system: first of two parts. *New England Journal of Medicine*. 2000;343:37-49.
26. Hildesheim A, Wang SS. Host and viral genetics and risk of cervical cancer: a review. *Virus Research*. 2002;89:229-40.



27. Mahmud SM, Robinson K, Richardson H, Tellier P-P, Ferenczy AS, Roger M, et al. HLA polymorphisms and cervical Human Papillomavirus infection in a cohort of Montreal University students. *Journal of Infectious Diseases*. 2007;196:82-90.
28. Ferguson R, Ramanakumar AV, Richardson H, Tellier P-P, Coutlée F, Franco EL, et al. Human leukocyte antigen (HLA)-E and HLA-G polymorphisms in human papillomavirus infection susceptibility and persistence. *Human Immunology*. 2011;72:337-41.
29. Metcalfe S, Roger M, Faucher M-C, Coutlée F, Franco EL, Brassard P. The association between human leukocyte antigen (HLA)-G polymorphisms and human papillomavirus (HPV) infection in Inuit women of northern Quebec. *Human immunology*. 2013.
30. Maciag PC, Schlecht NF, Souza PS, Rohan TE, Franco EL, Villa LL. Polymorphisms of the human leukocyte antigen DRB1 and DQB1 genes and the natural history of human papillomavirus infection. *Journal of Infectious Diseases*. 2002;186:164-72.
31. Simoes RT, Gonçalves MAG, Castelli EC, Júnior CM, Bettini JS, Discorde ML, et al. HLA-G polymorphisms in women with squamous intraepithelial lesions harboring human papillomavirus. *Modern Pathology*. 2009;22:1075-82.
32. Ferguson R, Ramanakumar AV, Koushik A, Coutlée F, Franco E, Roger M. Human leukocyte antigen G polymorphism is associated with an increased risk of invasive cancer of the uterine cervix. *International Journal of Cancer*. 2012;131:E312-E9.
33. Trottier H, Franco EL. The epidemiology of genital human papillomavirus infection. *Vaccine*. 2006;24:S4-S15.
34. Richardson H, Abrahamowicz M, Tellier P-P, Kelsall G, du Berger R, Ferenczy A, et al. Modifiable risk factors associated with clearance of type-specific cervical human papillomavirus infections in a cohort of university students. *Cancer Epidemiology Biomarkers & Prevention*. 2005;14:1149-56.
35. Richardson H, Kelsall G, Tellier P, Voyer H, Abrahamowicz M, Ferenczy A, et al. The natural history of type-specific human papillomavirus infections in female university students. *Cancer Epidemiology Biomarkers & Prevention*. 2003;12:485-90.
36. Hosmer DW, Lemeshow S. *Model-Building Strategies and Methods for Logistic Regression*. Applied Logistic Regression, Second Edition. 2000:91-142.
37. Goodman MT, Shvetsov YB, McDuffie K, Wilkens LR, Zhu X, Thompson PJ, et al. Prevalence, acquisition, and clearance of cervical human papillomavirus infection among women with normal cytology: Hawaii Human Papillomavirus Cohort Study. *Cancer Research*. 2008;68:8813-24.
38. Rouas-Freiss N, Moreau P, Menier C, Carosella ED. HLA-G in cancer: a way to turn off the immune system. *Seminars in cancer biology*; 2003: Elsevier. p. 325-36.
39. Wang SS, Hildesheim A. Viral and host factors in human papillomavirus persistence and progression. *JNCI Monographs*. 2003;2003:35-40.
40. Clements CS, Kjer-Nielsen L, Kostenko L, Hoare HL, Dunstone MA, Moses E, et al. Crystal structure of HLA-G: a nonclassical MHC class I molecule expressed at the fetal-maternal interface. *Proceedings of the National Academy of Sciences of the United States of America*. 2005;102:3360-5.

41. Nielson CM, Harris RB, Flores R, Abrahamsen M, Papenfuss MR, Dunne EF, et al. Multiple-type human papillomavirus infection in male anogenital sites: prevalence and associated factors. *Cancer Epidemiology Biomarkers & Prevention*. 2009;18:1077-83.
42. Vaccarella S, Franceschi S, Herrero R, Muñoz N, Snijders PJ, Clifford GM, et al. Sexual behavior, condom use, and human papillomavirus: pooled analysis of the IARC human papillomavirus prevalence surveys. *Cancer Epidemiology Biomarkers & Prevention*. 2006;15:326-33.
43. Manhart LE, Koutsky LA. Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia?: A meta-analysis. *Sexually Transmitted Diseases*. 2002;29:725-35.
44. Green J, De Gonzalez AB, Smith Jaa, Franceschi S, Appleby P, Plummer M, et al. Human papillomavirus infection and use of oral contraceptives. *British Journal of Cancer*. 2003;88:1713-20.
45. Vaccarella S, Herrero R, Dai M, Snijders PJ, Meijer CJ, Thomas JO, et al. Reproductive factors, oral contraceptive use, and human papillomavirus infection: pooled analysis of the IARC HPV prevalence surveys. *Cancer Epidemiology Biomarkers & Prevention*. 2006;15:2148-53.
46. Sharkey DJ, Tremellen KP, Jasper MJ, Gemzell-Danielsson K, Robertson SA. Seminal fluid induces leukocyte recruitment and cytokine and chemokine mRNA expression in the human cervix after coitus. *The Journal of Immunology*. 2012;188:2445-54.

## **TABLES AND FIGURES**

**Table 1: Associations between baseline exposures (significant at p<0.25) and cumulative HPV infection status**

Variable	Frequency (%)			OR (95% CI)	
	HPV-negative n=230 (42.8)	Monoinfection n=115 (21.4)	Coinfection n=192 (35.8)	Coinfection v. HPV-negative	Coinfection v. monoinfection
<b>Age at enrollment</b>					
17-20	96 (45.1)	42 (19.7)	75 (35.2)	1.00	1.00
21-23	61 (37.9)	34 (21.1)	66 (41.0)	1.39 (0.87-2.20)	1.09 (0.62-1.90)
24-26	32 (37.2)	21 (24.4)	33 (38.4)	1.32 (0.75-2.34)	0.88 (0.45-1.71)
≥27	41 (53.2)	18 (23.4)	18 (23.4)	0.56 (0.30-1.06)	0.56 (0.26-1.19)
<b>Race</b>					
White	178 (40.7)	93 (21.3)	166 (38.0)	1.00	1.00
Black/Hispanic <sup>a</sup>	19 (45.2)	8 (19.1)	15 (35.7)	0.85 (0.42-1.72)	1.05 (0.43-2.57)
Asian	33 (56.9)	14 (24.1)	11 (19.0)	<b>0.36 (0.18-0.73)</b>	0.44 (0.19-1.01)
<b>Age at first intercourse</b>					
<16	40 (33.3)	26 (21.7)	54 (45.0)	1.00	1.00
16-18	121 (43.4)	59 (21.1)	99 (35.5)	<b>0.61 (0.37-0.99)</b>	0.81 (0.46-1.43)
≥19	69 (50.0)	30 (21.7)	39 (28.3)	<b>0.42 (0.24-0.74)</b>	0.63 (0.32-1.22)
<b>Number of lifetime sex partners</b>					
0-1	75 (65.8)	19 (16.7)	20 (17.5)	1.00	1.00
2-4	76 (44.2)	36 (20.9)	60 (34.9)	<b>2.96 (1.63-5.39)</b>	1.58 (0.75-3.36)
5-9	48 (33.6)	30 (21.0)	65 (45.4)	<b>5.08 (2.74-9.43)</b>	2.06 (0.96-4.41)
≥10	31 (28.7)	30 (27.8)	47 (43.5)	<b>5.69 (2.91-11.11)</b>	1.49 (0.68-3.24)
<b>Number of new sex partners<sup>b</sup></b>					
0	120 (52.9)	54 (23.8)	53 (23.3)	1.00	1.00
1	78 (47.9)	31 (19.0)	54 (33.1)	1.57 (0.98-2.52)	1.78 (0.99-3.18)
≥2	32 (21.8)	30 (20.4)	85 (57.8)	<b>6.01 (3.58-10.11)</b>	<b>2.89 (1.64-5.07)</b>
<b>Anal sex<sup>c</sup></b>					
Never	182 (45.7)	83 (20.8)	133 (33.4)	1.00	1.00
Ever	43 (34.5)	32 (23.0)	59 (42.5)	<b>1.68 (1.08-2.62)</b>	1.15 (0.69-1.92)
<b>Oral contraceptive use<sup>b</sup></b>					
Regularly	156 (42.9)	83 (22.8)	125 (34.3)	1.00	1.00
Sometimes	21 (36.2)	10 (17.2)	27 (46.6)	1.61 (0.87-2.97)	1.79 (0.82-3.90)
Never	53 (46.1)	22 (19.1)	40 (34.8)	0.94 (0.59-1.51)	1.21 (0.67-2.18)
<b>Frequency of sex/week<sup>b</sup></b>					
<1 time	52 (39.1)	24 (18.1)	57 (42.9)	1.00	1.00
1-3 times	127 (44.4)	70 (24.5)	89 (31.1)	0.64 (0.40-1.02)	<b>0.54 (0.30-0.95)</b>
4-6 times	40 (40.8)	18 (18.3)	40 (40.8)	0.91 (0.51-1.63)	0.94 (0.45-1.95)
≥7 times	11 (55.0)	3 (15.0)	6 (30.0)	0.50 (0.17-1.44)	0.84 (0.19-3.65)
<b>History of yeast infections<sup>c</sup></b>					
No	126 (47.9)	53 (20.2)	84 (31.9)	1.00	1.00
Yes	104 (38.0)	62 (22.6)	108 (39.4)	<b>1.56 (1.06-2.29)</b>	1.10 (0.69-1.75)
<b>History of STIs<sup>c,d</sup></b>					
No	219 (44.9)	101 (20.7)	168 (34.4)	1.00	1.00
Yes	11 (22.4)	14 (28.6)	24 (49.0)	<b>2.84 (1.36-5.97)</b>	1.03 (0.51-2.08)
<b>Chlamydia<sup>c</sup></b>					
No	226 (44.3)	106 (20.8)	178 (34.9)	1.00	1.00
Yes	4 (14.8)	9 (33.3)	14 (51.9)	<b>4.44 (1.44-13.74)</b>	0.93 (0.39-2.21)
<b>Herpes (HSV-2)<sup>c</sup></b>					
No	226 (43.4)	112 (21.5)	183 (35.1)	1.00	1.00
Yes	4 (25.0)	3 (18.8)	9 (56.3)	2.78 (0.84-9.17)	1.84 (0.49-6.92)
<b>Vegetable consumption<sup>c</sup></b>					
≥1 serving per day	47 (45.2)	21 (20.2)	36 (34.6)	1.00	1.00
>1 serving per week	103 (40.7)	51 (20.2)	99 (39.1)	1.26 (0.75-2.10)	1.13 (0.60-2.14)
1 serving per week	64 (44.1)	33 (22.8)	48 (33.1)	0.98 (0.55-1.74)	0.85 (0.42-1.70)
Rarely	16 (45.7)	10 (28.6)	9 (25.7)	0.73 (0.29-1.85)	0.53 (0.18-1.50)

<b>Alcohol consumption<sup>c</sup></b> (Drinks per week)						
	0	95 (48.7)	35 (18.0)	65 (33.3)	1.00	1.00
	1-3	77 (49.0)	31 (19.8)	49 (31.2)	0.93 (0.58-1.50)	0.85 (0.46-1.57)
	≥4	58 (31.4)	49 (26.5)	78 (42.2)	<b>1.97 (1.24-3.13)</b>	0.86 (0.50-1.48)
<b>Average cigarettes smoked/day<sup>c</sup></b>						
	Nonsmoker	152 (48.0)	66 (20.8)	99 (31.2)	1.00	1.00
	<1	10 (43.5)	6 (26.1)	7 (30.4)	1.08 (0.40-2.92)	0.78 (0.25-2.42)
	1-5	34 (37.8)	17 (18.9)	39 (43.3)	<b>1.76 (1.04-2.98)</b>	1.53 (0.80-2.93)
	>5	34 (37.8)	26 (24.3)	47 (43.9)	<b>2.12 (1.28-3.53)</b>	1.21 (0.68-2.13)
	Any	78 (35.5)	49 (22.3)	93 (42.3)	<b>1.83 (1.24-2.71)</b>	1.27 (0.79-2.02)
<b>HLA-DQB1*03</b>						
	No	70 (37.0)	44 (23.3)	75 (39.7)	1.00	1.00
	Yes	160 (46.0)	71 (20.4)	117 (33.6)	0.68 (0.46-1.02)	0.97 (0.60-1.55)
<b>HLA-DQB1*06:02</b>						
	No	187 (44.3)	92 (21.8)	143 (33.9)	1.00	1.00
	Yes	43 (37.4)	23 (20.0)	49 (42.6)	1.49 (0.94-2.37)	1.37 (0.78-2.40)
<b>HLA-DRB1*15:01</b>						
	No	176 (44.2)	87 (21.9)	135 (33.9)	1.00	1.00
	Yes	54 (38.9)	28 (20.1)	57 (41.0)	1.38 (0.89-2.13)	1.31 (0.78-2.22)
<b>HLA-G*01:01:01</b>						
	No	71 (41.3)	46 (26.7)	55 (32.0)	1.00	1.00
	Yes	159 (43.6)	69 (18.9)	137 (37.5)	1.11 (0.73-1.69)	<b>1.66 (1.02-2.70)</b>
<b>HLA-G*01:01:03</b>						
	No	205 (43.8)	94 (20.1)	169 (36.1)	1.00	1.00
	Yes	25 (36.2)	21 (30.4)	23 (33.3)	1.12 (0.61-2.04)	0.61 (0.32-1.16)
<b>HLA-G*01:01:05</b>						
	No	216 (42.9)	110 (21.9)	177 (35.2)	1.00	1.00
	Yes	14 (41.2)	5 (14.7)	15 (44.1)	1.31 (0.62-2.78)	1.86 (0.66-5.27)
<b>HLA-G*01:01:07</b>						
	No	221 (42.9)	108 (21.0)	186 (36.1)	1.00	1.00
	Yes	9 (40.9)	7 (31.8)	6 (27.3)	0.79 (0.28-2.27)	0.50 (0.16-1.52)

- These categories combined due to small numbers
- In the last year prior to enrollment
- In lifetime
- Includes trichomoniasis, chlamydia, herpes, syphilis, gonorrhea, genital sores
- In the past 5 years

**Table 2: Multivariate models with independent predictors of cumulative HPV coinfection**

Variable	Cumulative Coinfection v. HPV-negative (n=422)	Cumulative Coinfection v. monoinfection (n=307)
	OR <sup>a</sup> (95% CI)	OR <sup>a</sup> (95% CI)
<b>Age at enrollment</b>		
≤ 26	1.00	1.00
≥ 27	<b>0.34 (0.17-0.67)</b>	0.54 (0.25-1.17)
<b>Number of lifetime sex partners</b>		
0-1	1.00	1.00
2-4	<b>2.15 (1.14-4.08)</b>	1.19 (0.54-2.65)
≥ 5	<b>3.62 (1.88-6.95)</b>	1.22 (0.56-2.66)
<b>Number of new sex partners<sup>b</sup></b>		
0	1.00	1.00
1	1.33 (0.80-2.21)	1.57 (0.85-2.89)
≥ 2	<b>3.87 (2.16-6.93)</b>	<b>2.74 (1.48-5.08)</b>
<b>History of STIs<sup>c</sup></b>		
No	1.00	1.00
Yes	<b>2.96 (1.31-6.69)</b>	1.06 (0.50-2.24)
<b>HLA-DQB1*06:02</b>		
No	1.00	1.00
Yes	<b>1.83 (1.08-3.09)</b>	1.62 (0.90-2.93)
<b>HLA-G*01:01:03</b>		
No	1.00	1.00
Yes	1.12 (0.47-2.71)	<b>0.34 (0.14-0.81)</b>
<b>HLA-G*01:01:05</b>		
No	1.00	1.00
Yes	1.06 (0.35-3.21)	<b>6.44 (1.66-24.95)</b>

- a. Mutually adjusted for all other variables in a column
- b. In the year prior to enrollment
- c. In lifetime; includes trichomoniasis, chlamydia, herpes, syphilis, gonorrhea, genital sores

**Table 3: Multivariate models with independent predictors of concurrent HPV coinfection**

Variable	Concurrent Coinfection v. HPV-negative (n=1954 visits) OR <sup>a</sup> (95% CI)	Concurrent Coinfection v. mono-infection (n=746 visits) OR <sup>a</sup> (95% CI)
<i>Baseline exposures</i>		
<b>Age at enrollment</b>		
≤26	1.00	1.00
≥27	<b>0.38 (0.17-0.87)</b>	0.54 (0.24-1.25)
<b>Age at first intercourse</b>		
<16	1.00	1.00
16-18	1.21 (0.76-1.94)	1.60 (0.97-2.63)
≥19	1.10 (0.58-2.06)	1.18 (0.61-2.27)
<b>Number of lifetime sex partners</b>		
0-1	1.00	1.00
2-4	<b>3.13 (1.60-6.14)</b>	1.12 (0.55-2.27)
≥5	<b>4.90 (2.38-10.10)</b>	1.07 (0.51-2.25)
<i>Time-dependent exposures</i>		
<b>Number of new sex partners<sup>b</sup></b>		
0	1.00	1.00
1	<b>1.64 (1.22-2.20)</b>	<b>1.59 (1.09-1.34)</b>
≥2	<b>2.07 (1.53-2.81)</b>	<b>1.52 (1.03-2.24)</b>
<b>Frequency of sex per week<sup>c</sup></b>		
<1 time	1.00	1.00
1-3 times	1.00 (0.75-1.34)	0.93 (0.62-1.38)
4-6 times	1.34 (0.95-1.88)	0.85 (0.50-1.44)
7+ times	0.96 (0.54-1.67)	0.43 (0.15-1.21)
<b>Oral contraceptive use<sup>c</sup></b>		
Regularly	1.00	1.00
Sometimes	1.26 (0.83-1.90)	<b>1.88 (1.08-3.26)</b>
Never	0.98 (0.73-1.32)	1.23 (0.83-1.82)
<b>Condom use<sup>c</sup></b>		
Regularly	1.00	1.00
Sometimes	1.19 (0.91-1.56)	1.24 (0.83-1.83)
Never	<b>1.33 (1.01-1.74)</b>	1.56 (1.00-2.44)

- a. Mutually adjusted for all other variables in a column
- b. Since the last 2 visits (~12 months)
- c. Since the last visit (~6 months)

## **FIGURE LEGENDS**



### **Figure 1: Flow charts for models**



Fig. 1

CUMULATIVE MODELS

CONCURRENT MODELS



# Cancer Epidemiology, Biomarkers & Prevention

**AACR** American Association  
for Cancer Research

## Determinants of human papillomavirus coinfections among Montreal university students: the influence of behavioural and biological factors

Michaela A Smith, Pierre-Paul Tellier, Michel Roger, et al.

*Cancer Epidemiol Biomarkers Prev* Published OnlineFirst February 25, 2014.

**Updated version** Access the most recent version of this article at:  
doi:[10.1158/1055-9965.EPI-13-1255](https://doi.org/10.1158/1055-9965.EPI-13-1255)

**Author Manuscript** Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://cebp.aacrjournals.org/content/early/2014/02/25/1055-9965.EPI-13-1255>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.